Abstract
Introduction: Consideration of the role of new therapeutic agents has taken new dimensions in light of emerging cardiovascular and renal data in addition to consideration of total cost of care. Simulated decision made through Artificial Intelligence systems such as GlucosePATH can be used to determine the fit of new compounds to treating type 2 diabetes. Glucokinase activators are not available as therapeutic agents in the U.S.A. Phase 3 data of dorzagliatin was used to model projected retail cost in the current environment. Methods: A data set of 366 patients with HbA1c > 7 was drawn from a distribution of patients from the GlucosePATH database. Total monthly cost of care was computed based on the mean retail cost drawn from the GoodRX API. Using scores drawn from GlucosePATH, drugs were redistributed to find the lowest total cost at which the population's score was > 70 out of 100. Total retail cost of care averaged $371.39 per month per patient for the 366 patients. Redistributed medication at this price generated a mean composite score of 80.36 at a projected mean HbA1c of 7.5. Two price points were established for dorzagliatin. The "maximal price" (MP) is the highest price at which use of the agent in the population does not exceed the control group’s retail cost of care and the composite score threshold is met. (That is, introducing the new agent does not increase cost or worsen results for the population.) The "maximal revenue" (MR) is the price at which the agent’s manufacturer maximizes their gross revenue for the agent in the population. Results: Price optimization for dorzagliatin showed a MP of approximately $145. At its MP, dorzagliatin would be prescribed to approximately 5% of the population with mean composite score of 80.17 and mean HbA1c 7.5. At dorzagliatin’s MR of approximately $75 per month, it would be prescribed to approximately 23% of the population and generate a mean composite score of 80.54 with a mean HbA1c of 7.5. Disclosure B. Bennett: None. S. Allen: None. B. Eilerman: Advisory Panel; Self; Dexcom, Inc., Medtronic. Speaker’s Bureau; Self; AbbVie Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Corcept Therapeutics, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc. Stock/Shareholder; Self; PATH Decision Support Software LLC. L.J. Testa: Stock/Shareholder; Self; PATH Decision Support Software LLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
